Research Article

Impact of High Glucose and Proteasome Inhibitor MG132 on Histone H2A and H2B Ubiquitination in Rat Glomerular Mesangial Cells

Chenlin Gao, Guo Chen, Li Liu, Xia Li, Jianhua He, Lan Jiang, Jianhua Zhu, and Yong Xu

Department of Endocrinology, Affiliated Hospital of Luzhou Medical College, Luzhou 646000, China

Correspondence should be addressed to Yong Xu; xywyll@yahoo.com.cn

Received 28 October 2012; Revised 12 January 2013; Accepted 17 February 2013

Copyright © 2013 Chenlin Gao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Hyperglycemia plays a pivotal role in the development of diabetic nephropathy (DN) and may be related to epigenetic metabolic memory. One of the most crucial epigenetic mechanisms is histone modification, which is associated with the expression of a fibrosis factor in vascular injury. Aim. In this study, we investigated the ubiquitination of histones H2A and H2B to explore the epigenetic mechanisms of DN. Materials and Methods. The GMCs were cultured as follows: normal group, high glucose group, mannitol group, and intervention group. After 12 hr, 24 hr, and 48 hr, histones ubiquitination, transforming growth factor-β (TGF-β), and fibronectin (FN) were measured using WB, RT-PCR, and IF. Result. High glucose can induce the upregulation of FN. H2A ubiquitination in GMCs increased in high glucose group (P < 0.01), whereas it decreased significantly in intervention group (P < 0.05). In contrast, H2B ubiquitination decreased with an increasing concentration of glucose, but it was recovered in the intervention group (P < 0.05). Expression of TGF-β changed in response to abnormal histone ubiquitination. Conclusions. The high glucose may induce H2A ubiquitination and reduce H2B ubiquitination in GMCs. The changes of histone ubiquitination may be due in part to DN by activating TGF-β signaling pathway.

1. Introduction

Diabetic nephropathy (DN) is one of the most devastating microvascular complications of diabetes, which remains the most common cause for end stage renal disease (ESRD). The prevalence of diabetes and the patients suffering from diabetic microvascular complications is increasing worldwide [1]. Nearly one-third of patients with diabetes develop nephropathy, and early diagnosis is critical in preventing long-term kidney loss [2]. However, the mechanisms that cause DN have not been completely clarified, and the treatment options are limited.

Hyperglycemia plays a pivotal role in activating various inflammatory pathways in the development and progression of DN. It induces the fibrotic factor transforming growth factor-β (TGF-β) and fibronectin (FN), the renin-angiotensin-aldosterone system (RAAS), and advanced glycation end products both directly and via gene transcription, which leads to thickening of the glomerular and tubular basement membranes, progressive accumulation of extracellular matrix (ECM) proteins, interstitial fibrosis, and glomerulosclerosis [3–6]. FN is one of the main ingredients of ECM and an important symbol of cell injury. The upgrade expression of FN will eventually lead to the development of diabetic nephropathy. Clinical trials have reported that strict glycemic control reduces the progression of diabetic complications over time. Diabetic complications, including chronic kidney disorders such as DN, have been shown to persist and progress even after glucose control has been achieved, possibly as a result of prior episodes of hyperglycemia that are considered the epigenetic metabolic memory [7]. Preliminary work using endothelial cells has shown that transient episodes of hyperglycemia can induce changes in gene expression that are dependent on the modification of histone tails (i.e., methylation) [8]. The persistence of such modifications has not been fully explained. Additional
studies regarding the epigenetic mechanisms involved are necessary to provide valuable new insights into the pathology of DN.

Posttranslational modifications of the aminoterminal tails of nucleosomal histones, including acetylation, methylation, ubiquitination, phosphorylation, and sumoylation, play key roles in modulating the chromatin structure and gene transcription that have been implicated in regulating the metabolism of diabetic complications [9]. The modification of histones by ubiquitination is a prominent epigenetic mark that may influence changes in gene expression and involves a variety of chromatin-based events, such as gene silencing and repair of DNA damage [10]. The majority of histone ubiquitination occurs on chromatin by the addition of a single ubiquitin molecule via isopeptide linkage to a specific lysine residue on the C-terminal tail of histones H2A and H2B. To a lesser extent, histones H1, H3, and H4 can be ubiquitylated in vivo, and ubiquitination of different histones has distinct functions [11]. However, the effects of histone ubiquitination on DN are unclear.

Recent research has indicated that histone modification is directly or indirectly related to diabetic attacks [12–15]. Histone acetylation can activate the TGF-β signaling pathway, which plays an important role in DN renal fibrosis. Similarly, DN is associated with increased renal H3K9 and H3K23 acetylation, H3K4 dimethylation, and H3 phosphorylation at serine 10, which enhances chromatin unfolding and gene expression [16, 17]. To date, it is unknown whether histone ubiquitination is involved in interstitial fibrosis and glomerulosclerosis in DN or whether the effects of hyperglycemia on such epigenetic events can be mediated through TGF-β signaling pathways. MG132, a proteasome inhibitor, is suggested to attenuate hypertension-induced cardiac remodeling and dysfunction by downregulating the levels of TGF-β [18]. Whether ubiquitin proteasome inhibitors can inhibit renal fibrosis which was followed by activation of the TGF-β signaling pathway in diabetic nephropathy remain unclear. So, additional research to develop new treatments for DN is necessary. In this study, we evaluated the influence of high glucose on the induction of histone H2A ubiquitination, reduced histone H2B ubiquitination in GMCs, and changes in the expression of TGF-β followed by abnormal histone ubiquitination. MG132, which acts as a ubiquitin proteasome inhibitor, may prevent the alterations in H2A and H2B ubiquitination induced by high glucose.

2. Materials and Methods

2.1. Cell Culture. Cell culture media and fetal bovine serum were purchased from Hyclone (USA). Rat glomerular mesangial cells (HBZY-1) were purchased from the Preservation Center at Wuhan University and maintained in low glucose DMEM with 10% fetal bovine serum at 37°C and 5% CO2. GMCs were used between the 2nd and 5th passages for all experiments and randomly divided into the following six groups:

(i) the normal control group (NC group), with medium containing 5.6 mmol/L glucose,

(ii) the 10 mmol/L glucose group (HG1 group), with medium containing 10 mmol/L glucose,

(iii) the 20 mmol/L glucose group (HG2 group), with medium containing 20 mmol/L glucose,

(iv) the 30 mmol/L glucose group (HG3 group), with medium containing 30 mmol/L glucose,

(v) the osmotic pressure group as a control (OP group), with medium containing 5.6 mmol/L glucose + 22.4 mmol/L mannitol,

(vi) the MG132 intervention group (MI group), with medium containing 30 mmol/L glucose + 1 μmol/L MG132. MG132 was added to the culture medium to block the ubiquitination of histone.

Each group had been cultured for 12 hr, 24 hr, and 48 hr.

2.2. Protein Extraction and Western Blot. Total proteins were isolated from GMCs using a total protein extraction kit (Kaiji, Shanghai, China). The protein concentration was determined using BCA analysis (Beyotime, Shanghai, China). Western blotting was performed as previously described [19]. Immunoblot analysis was performed using anti-ubiquityl-histone H2A (mouse, 1:1000; Millipore, USA), anti-ubiquityl-histone H2B (rabbit, 1:1000; CST, USA), and anti-GAPDH and actin (rabbit, 1:1000; Beyotime, Shanghai, China). Horseradish peroxidase-conjugated secondary antibodies (anti-rabbit and anti-mouse) were obtained from the Beyotime Institute of Biotechnology, Shanghai, China. Proteins were detected using the enhanced chemiluminescence system and ECL Hyperfilm (Millipore, USA).

2.3. RNA Extraction and Semiquantitative PCR. Total RNA was extracted from GMCs using an RNA extraction kit (Tiangen Biotech, Beijing, China). A total of 500 ng RNA was reverse transcribed at a final volume of 20 μL using a Takara RNA PCR kit (Baoshengwu, Dalian, China). Four microliters of cDNA were amplified in a gradient thermal cycler (Eppendorf, Germany) using the PCR Master Mix (Baoshengwu, Dalian, China). The results were determined using a UV transilluminator and normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene expression. The primer sequences were as follows: histone H2A ubiquitination (uH2A), forward, 5’-GCA CCC TGA CCT TGC CTA T-3’, reverse, 5’-CCT TCC CAG ACT CCA CCA T-3’, histone H2B ubiquitination (uH2B), forward, 5’-GCA CCC TGA CCT TGC CTA T-3’, reverse, 5’-CCT TGC TTC CCA CCA CCA CCA T-3’, transforming growth factor-β (TGF-β), forward, 5’-ATG GTG GAC GCG AAC AAC-3’, reverse, 5’-GAG CAC TGA AGC GAA AGC-3’, FN, forward, 5’-TGC CGA ATG AGG AGA-3’, reverse, 5’-CAA TCA CCA CTG CCA AAG CC-3’, and GAPDH, forward, 5’-CCT CAA GAT TGT CAG CAA T-3’, reverse, 5’-CCA TGC ACA GTC TCC TGA GT-3’.

2.4. Immunofluorescence. Cells were grown on coverslips in 6-well plates. After overnight adherence, the cells were treated with media containing high glucose, mannitol, and the MI.
Figure 1: Cell picture in each group of GMCs by inverted phase contrast microscope (×100). No significant changes in cell morphology.

Figure 2: The mRNA levels of FN in each group of GMCs. (a) RT-PCR strip chart for different concentrations of glucose. FN mRNA increased in the high glucose group, especially in HG3 group. (c) The corresponding relative gray value statistics graph of the mRNA level. *P < 0.05 versus NC group, †P < 0.01 versus NC group, and ‡P < 0.05 versus HG2 group. (b) RT-PCR strip chart for different times. The expression of FN mRNA increased over time. (d) The corresponding relative gray value statistics graph of the mRNA level. *P < 0.01 versus NC group.

media for 24 hr. The cells were fixed in 4% paraformaldehyde (Pierce) and permeabilized in 0.2% Tween 20 (Sigma) for 10 min after being washed briefly with PBS. The cells were blocked with 5% goat serum for 1 hr at room temperature and incubated overnight with primary antibodies followed by washes with PBS. The cells were incubated for 40 min with the appropriate secondary antibody conjugated to the FITC fluorescent dye. DAPI (4',6'-diamino-2-phenylindole) was used to stain the nucleus in the cells. The coverslips were washed and mounted onto slides using fluorescent mounting medium (Beyotime, Shanghai, China). The control cells were incubated without a primary antibody. Images were taken with a DMI 2i laser scanning confocal microscope (Leica, Germany).

2.5. Statistics. All experimental data were obtained from three independent experiments performed in triplicate. Data were expressed as the mean ± SD (± s), which were analyzed using SPSS 11.5 statistical software. Statistical differences were calculated using one-way analysis of variance (one-way ANOVA) to compare more than two groups, followed by the LSD test for multiple comparisons. P < 0.05 was defined as statistically significant.

3. Results

The cellular morphology in different glucose culture medium is not significantly changing (Figure 1), but the expression of FN increased in the high glucose group over time, especially in HG3 group for 48 hr (Figure 2).

After 48 hr in culture, Western blot analysis showed low H2A ubiquitin expression in the NC group. Expression was higher in the high glucose group compared to the NC group (P < 0.01) in a concentration dependent manner. The strongest expression was in the 30 mmol/L high glucose group (P < 0.01). In contrast, H2B ubiquitination expression was strong in the NC group. There were no significant differences in H2B ubiquitination expression in the 10 mmol/L high glucose group compared to the NC group (P = 0.327). Expression was lower in the 20 and 30 mmol/L high glucose groups compared to the NC group (P < 0.01) and was the
The expression of histone H2A and H2B ubiquitination in each group of GMCs by Western blot (48 hr). (a) uH2A and uH2B proteins at different glucose concentrations and high osmotic pressure at 48 hr: uH2A increased in the high glucose group and uH2B decreased as the glucose concentrations increased; they had the most significant changes in the HG3 group, but there were no apparent differences between the NC group and the OP group. (b) The gray graph shows the relative statistical values of uH2A for each group. The expression of the uH2A increased in the high glucose group, especially, in the HG3 group. *p < 0.01 versus NC group, #p < 0.03 versus HG1 group, and **p < 0.05 versus HG2 group. (c) The gray graph shows the relative statistical values of uH2B for each group. The expression of the uH2B proteins decreased by concentration dependency, obviously in HG3 group. *p < 0.01 versus NC group, #p < 0.03 versus HG1 group, and **p < 0.05 versus HG2 group.

Weakest in the 30 mmol/L high glucose group. There were no differences between the OP and NC groups regarding the ubiquitination of H2A and H2B (P > 0.05) (Figure 3). The expression of the uH2A protein increased at various time intervals in the HG3 group, particularly after 24 hr in culture. The increased expression of uH2A at various time points was statistically significant (P < 0.01). Expression of the uH2B protein was significantly reduced in a time dependent manner (P < 0.01) (Figure 4). After MG132 intervention, the expression of uH2A was significantly decreased compared to expression in the 30 mmol/L glucose group (P < 0.05). In contrast, the expression of uH2B was recovered in the MI group compared to the HG3 group (P < 0.05) (Figure 5). The same results were detected using cell immunofluorescent staining and laser scanning confocal microscopy applications (Figure 6).

The expression of TGF-β mRNA increased in the high glucose group compared to the NC group (P < 0.01) in a concentration and time dependent manner (Figure 7). And it decreased along with the normalization of uH2A and H2B protein expression (P < 0.05), although the mRNA levels of uH2A and H2B were not statistically different in each group (Figure 8).

4. Discussion

Hyperglycemia plays an important role in the development and progression of DN, which can induce the expression of FN and cause cell injury, but the DNA sequence changes cannot solely explain the heritable patterns of gene expression. However, hyperglycemic memory may explain why intensive glucose control has failed to improve cardiovascular outcomes in patients with diabetes, although the molecular mechanisms of this phenomenon remain to be elucidated. The current study found histone modifications can change the state of evacuation and aggregation in chromatin by affecting compatibility between the histones and double-stranded DNA and influencing the affinity of transcription factors for structural gene promoters, which can regulate the
expression of genes [20]. Recent studies have shown that diabetes-induced epigenetic changes can affect gene expression in vascular endothelial cells and vascular smooth muscle cells and long-lasting changes in epigenetic modifications at key inflammatory gene promoters following exposure to diabetic conditions [7, 21]. Histone acetylation attenuates epidermal growth factor signaling, which has a key role in the development of DN, and genome-wide studies have shown cell-type specific changes in histone methylation patterns under conditions of DN [22, 23]. And in diabetic retinopathy, histone acetylation was significantly increased in retinas from diabetic rats and contributed to the hyperglycemia-induced upregulation of proinflammatory proteins and thereby to the development of diabetic retinopathy [24]. In DN, histone acetylation, specific histone acetyl transferases, and histone deacetylases significantly enhanced TGF-β1-induced gene expression in rat mesangial cells and in glomeruli from diabetic mice and augmented glomerular dysfunction linked to diabetic nephropathy [25]. Histone methylation has also gained much attention as potential molecular mechanisms underlying metabolic memory and DN. The specific Set7 methyltransferase is the best characterised lysine enzyme, which showed high expression in DN. Furthermore, the contribution of Set7 to the aetiology of diabetic complications may extend to other transcriptional events through methylation of nonhistone substrates [26, 27]. However, little is known about histone ubiquitination in diabetic nephropathy. In this study, we found high glucose may cause cell damage, induce the ubiquitination of histone H2A, and reduce the ubiquitination of histone H2B in GMCs.

The results indicate that histone H2A and H2B ubiquitination may be involved in the development and progression of DN as an epigenetic mechanism. Although the mechanisms of action vary for different histones, ubiquitination of histone H2A K119 may induce DN and ubiquitination of histone H2B K120 has been shown to delay the onset of DN.

TGF-β has been implicated in various human disorders, including vascular and renal diseases, and is a primary fibrotic factor. Diabetic nephropathy (DN) is a chronic renal complication characterized by thickening of the glomerular and tubular basement membranes and progressive accumulation of extracellular matrix (ECM) proteins, such as type I and type IV collagens, fibronectin, and laminin in the tubular interstitium and mesangium. TGF-β increases ECM accumulation and plays a major role in the development of chronic renal diseases through the induction of a downstream effector, which is a connective tissue growth factor, and by decreasing matrix degradation through the inhibition of
proteases or activation of protease inhibitors [28]. The TGF-β signaling pathway is controlled by many factors, including histone modification and epigenetic chromatin marks, such as histone H3 lysine methylation in TGF-β1-induced gene expression in rat mesangial cells under normal and high glucose conditions. TGF-β1 has been shown to increase the expression of ECM-associated genes, the connective tissue growth factor collagen-α1, and plasminogen activator inhibitor-1. Increased levels of histone H3 K4 methylation associated with active genes and decreased levels of histone H3 K9 methylation at these gene promoters accompany changes in expression [29]. TGF-β1 also increased the expression of H3 K4 methyltransferase SET7/9 and recruitment to these promoters. SET7/9 gene silencing with siRNAs significantly attenuated TGF-β1-induced ECM gene expression [9].

In this study, we did not examine changes in the mRNA levels of uH2A and uH2B as a consequence of uH2A and uH2B proteins stimulation by high glucose. This implies that there is no difference in the gene order of histones H2A and H2B, except for posttranslational modifications, including histone ubiquitination. We observed that the mRNA level of TGF-β dramatically increased followed by changes in uH2A and uH2B proteins. In summary, changes in uH2A and uH2B protein expression induced by high glucose in GMCs may enhance the activation of TGF-β and influence the pathogenesis of DN.

A recent study reported that the ubiquitin proteasome inhibitor MG132 has an antifibrotic function. MG132 exerts an antifibrotic effect by simultaneously downregulating type I collagen and a tissue inhibitor of metalloproteinase-1 and upregulating metalloproteinase-1 production in human dermal fibroblasts [30]. Tubular injury in a rat model of type 2 diabetes was shown to be prevented by MG132 by reducing renal tubule interstitial fibrosis [31]. Several studies have shown that MG132 has an effect on mitigating renal fibrosis by inhibiting the expression of kidney fibronectin mRNA in rats with early diabetic nephropathy and could improve proteinuria and other symptoms [32].

Research on histone ubiquitination is scarce, and inhibitors that can effectively and specifically block the ubiquitination of histones have not been described. The process of histone ubiquitination is similar to the ubiquitination of other proteins. MG132 is a specific ubiquitin proteasome inhibitor that can inhibit activation of the TGF-β
Figure 6: The expression of histone H2A and H2B ubiquitination in GMCs by immunofluorescent staining and laser scanning confocal microscopy applications. A1, NC group, B1, HG3 group, C1, MI group, D1, OP group, E1, negative control, and A2, B2, C2, D2, and E2 represent the corresponding groups of nuclear stains. (a) uH2A protein and (b) uH2B protein. uH2A and uH2B proteins were detected in the nucleus as green fluorescence overlapping with the blue fluorescence emitted by the nuclear stains DAPI. The uH2A protein was not detected in the NC group, but it was prominent in the HG3 group. The protein was strongly detected in the MG132 intervention group, which did not significantly change as a result of high osmotic pressure. The results for the uH2B protein were in contrast to the uH2A results.

The proteasome inhibitor MG132 induces apoptosis. For example, MG132 inhibited the PI3K/Akt and NFκB pathways, promoted mitochondrial depolarization, and decreased the concentration of mitochondrial antiapoptotic protein. MG132 also mediated activation of p38-JNK1/2 signaling and enhanced selective apoptosis in glioblastoma cells [34, 35]. MG132 is promising for cancer treatment because it markedly inhibited the growth of malignant tumor cells and arrested cells in the G2/M phase of the cell cycle, and the cells become apoptotic [36]. Strom and Parslen reported that MG132 inhibited the ubiquitin proteasome, which degrades the apoptosis inducer NGFI-B and is a nuclear receptor [37]. Thakur suggested that MG132 inhibits histone deacetylation by increasing the degradation of histone deacetylase induced by green tea polyphenols in a prostate cancer cell line, followed by cell arrest and apoptosis [38]. Therefore, the ubiquitin proteasome inhibitor MG132 could inhibit the proteasome and induce apoptosis. Possible answers regarding the causes of histone ubiquitination were identified in this study, but the detailed mechanisms involved will require additional research. Determining the specific inhibitors of signaling pathway, which is important in the development of fibrosis in DN [33]. However, there is not any evidence in the literature about whether MG132 can inhibit histone ubiquitination disorders or eliminate epigenetic metabolic memory to treat DN. Our experiments show that disorders involving histone H2A and H2B ubiquitination can exhibit an apparent reversal trend based on treating rat glomerular mesangial cells with MG132 and 30 mmol/L high glucose. After eliminating the dysfunction of histone ubiquitination, the expression of TGF-β mRNA was inhibited following MG132 intervention. This suggests that ubiquitin proteasome inhibitors may have a positive function in the treatment of diabetic nephropathy by inhibiting the disorders involving histone H2A and H2B ubiquitination that affects gene expression of TGF-β.
histone ubiquitination and discovering the role of histone ubiquitination in diabetic nephropathy renal fibrosis remain a challenge.

In conclusion, we demonstrated that the high glucose may induce the ubiquitination of histone H2A and reduce the ubiquitination of histone H2B in GMCs. The changes of histone ubiquitination in GMCs could activate TGF-β signaling pathway involved in the pathogenesis of diabetic nephropathy.

Acknowledgments

This work was supported by Grants from the National Natural Science Foundation of China (30670980). The authors would like to thank the Neurobiology Laboratory, Clinical Center Laboratory, and Cordis-myoelectricity Laboratory for technical assistance.

References

[1] C. Hu, R. Zhang, W. Yu et al., “CPVL/CHN2 genetic variant is associated with diabetic retinopathy in Chinese type 2 diabetic patients,” Diabetes, vol. 60, no. 11, pp. 3085–3089, 2011.
[2] D. Choudhury, M. Tuncel, and M. Levi, “Diabetic nephropathy—a multifaceted target of new therapies,” Discovery Medicine, vol. 10, no. 54, pp. 406–415, 2010.
[3] N. A. Calcutt, M. E. Cooper, T. S. Kern, and A. M. Schmidt, “Therapies for hyperglycaemia-induced diabetic complications:...
from animal models to clinical trials,” Nature Reviews Drug Discovery, vol. 8, no. 5, pp. 417–429, 2009.

[4] V. D’Agati and A. M. Schmidt, “RAGE and the pathogenesis of chronic kidney disease,” Nature Reviews Nephrology, vol. 6, no. 6, pp. 352–360, 2010.

[5] A. E. Declèves and K. Sharma, “New pharmacological treatments for improving renal outcomes in diabetes,” Nature Reviews Nephrology, vol. 6, no. 6, pp. 371–380, 2010.

[6] P. Ruggenenti, P. Cravedi, and G. Remuzzi, “Optimizing allocation of kidney from older donors,” American Journal of Transplantation, vol. 11, no. 1, pp. 182–183, 2011.

[7] L. M. Villeneuve, M. A. Reddy, and R. Natarajan, “Epigenetics: deciphering its role in diabetes and its chronic complications,” Clinical and Experimental Pharmacology Physiology, vol. 38, no. 7, pp. 451–459, 2011.

[8] S. Tonna, A. El-Osta, M. E. Cooper, and C. Tikellis, “Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms,” Nature Reviews Nephrology, vol. 6, no. 6, pp. 332–341, 2010.

[9] G. Sun, M. A. Reddy, H. Yuan, L. Lanting, M. Kato, and R. Natarajan, “Epigenetic histone methylation modulates fibrotic gene expression,” Journal of the American Society of Nephrology, vol. 21, no. 12, pp. 2069–2080, 2010.

[10] T. Kouzarides, “Chromatin modifications and their function,” Cell, vol. 128, no. 4, pp. 693–705, 2007.

[11] M. Higashi, S. Inoue, and T. Ito, “Core histone H2A ubiquitylation and transcriptional regulation,” Experimental Cell Research, vol. 316, no. 17, pp. 2707–2712, 2010.

[12] D. Brasacchio, J. Okabe, C. Tikellis et al., “Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail,” Diabetes, vol. 58, no. 5, pp. 1229–1236, 2009.

[13] A. El-Osta, D. Brasacchio, D. Yao et al., “Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia,” The Journal of Experimental Medicine, vol. 205, no. 10, pp. 2409–2417, 2008.

[14] A. L. Siebel, A. Z. Fernandez, and A. El-Osta, “Glycemic memory associated epigenetic changes,” Biochemical Pharmacology, vol. 80, no. 12, pp. 1853–1859, 2010.

[15] L. M. Villeneuve, M. Kato, M. A. Reddy, M. Wang, L. Lanting, and R. Natarajan, “Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suvin3h1,” Diabetes, vol. 59, no. 11, pp. 2904–2915, 2010.

[16] H. Noh, E. Y. Oh, J. Y. Seo et al., “Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-β1-induced renal injury,” American Journal of Physiology—Renal Physiology, vol. 297, no. 3, pp. F729–F738, 2009.

[17] R. Anand and R. Marmorstein, “Structure and mechanism of lysine-specific demethylase enzymes,” The Journal of Biological Chemistry, vol. 282, no. 49, pp. 35425–35429, 2007.

[18] Y. Ma, B. Chen, D. Liu et al., “MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-κB/TGFβ1 pathway,” Biochemical Pharmacology, vol. 81, no. 10, pp. 1228–1236, 2011.

[19] D. Fang, H. Guan, J. Liu et al., “Early intensive insulin therapy attenuates the p38 pathway in the renal cortex and indices of nephropathy in diabetic rats,” Endocrine Journal, vol. 59, no. 1, pp. 81–90, 2012.

[20] P. D. Gluckman, M. A. Hanson, T. Buklijas, F. M. Low, and A. S. Beedle, “Epigenetic mechanisms that underpin metabolic and cardiovascular diseases,” Nature Reviews Endocrinology, vol. 5, no. 7, pp. 401–408, 2009.

[21] T. Mitić and C. Emanuelli, “Diabetes-induced epigenetic signature in vascular cells,” Endocrine, Metabolic & Immune Disorders Targets, vol. 12, no. 2, pp. 107–117, 2012.

[22] R. E. Gilbert, Q. Huang, K. Thai et al., “Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor,” Kidney International, vol. 79, no. 12, pp. 1312–1321, 2011.

[23] M. A. Reddy and R. Natarajan, “Epigenetics in diabetic kidney disease,” Journal of the American Society of Nephrology, vol. 22, no. 12, pp. 2182–2185, 2011.

[24] C. S. Kadiyala, L. Zheng, Y. Du et al., “Acetylation of retinal histones in diabetes increases inflammatory proteins: effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC),” The Journal of Biological Chemistry, vol. 287, no. 31, pp. 25869–25880, 2012.

[25] H. Yuan, M. A. Reddy, G. Sun et al., “Involvement of p300/CREB and epigenetic histone acetylation in TGF-β1 mediated gene transcription in mesangial cells,” American Journal of Physiology—Renal Physiology, vol. 304, no. 5, pp. F601–F613, 2013.

[26] R. V. Intine and M. P. Sarras Jr., “Metabolic memory and chronic diabetes complications: potential role for epigenetic mechanisms,” Current Diabetise Reports, vol. 12, no. 5, pp. 551–559, 2012.

[27] S. T. Keating and A. El-Osta, “Chromatin modifications associated with diabetes,” Journal of Cardiovascular Translational Research, vol. 5, no. 4, pp. 399–412, 2012.

[28] M. Guha, Z. G. Xu, D. Tung, L. Lanting, and R. Natarajan, “Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes,” The Federation of American Societies for Experimental Biology Journal, vol. 21, no. 12, pp. 3355–3368, 2007.

[29] Y. Shi and J. Massagué, “Mechanisms of TGF-β signaling from cell membrane to the nucleus,” Cell, vol. 113, no. 6, pp. 685–700, 2003.

[30] S. Fineschi, W. Reith, P. A. Guerne, J. M. Dayer, and C. Chizzolini, “Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type 1 collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts,” The Federation of American Societies for Experimental Biology Journal, vol. 20, no. 3, pp. 562–564, 2006.

[31] Y. Takiyama, T. Harumi, J. Watanabe et al., “Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism,” Diabetes, vol. 60, no. 3, pp. 981–992, 2011.

[32] Y. Wang, Y. Xu, X. Fang et al., “Effects of MG132 on FNmRNA expression in early diabetic nephropathy rats,” Chinese Pharmacological Bulletin, vol. 27, no. 12, pp. 1773–1774, 2011.

[33] T. Sakairi, K. Hiromura, S. Takahashi et al., “Effects of proteasome inhibitors on rat renal fibrosis in vitro and in vivo,” Nephrology, vol. 16, no. 1, pp. 76–86, 2011.

[34] C. H. Choi, B. H. Lee, S. G. Ahn, and S. H. Oh, “Proteasome-inhibition-induced p38 MAPK/ERK signaling regulates autophagy and apoptosis through the dual phosphorylation
of glycogen synthase kinase 3β,” *Biochemical and Biophysical Research Communications*, vol. 418, no. 4, pp. 759–764, 2012.

[35] A. Zanotto-Filho, E. Braganhol, A. M. Battastini et al., “Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFκB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling,” *Investigational New Drugs*, vol. 30, no. 6, pp. 2252–2262, 2012.

[36] C. Saji, C. Higashi, Y. Niinaka, K. Yamada, K. Noguchi, and M. Fujimuro, “Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells,” *Biochemical and Biophysical Research Communications*, vol. 415, no. 4, pp. 573–578, 2011.

[37] B. O. Strøm and R. E. Paulsen, “Apoptosis inducer NGFI-B is degraded by the proteasome and stabilized by treatment with EGF,” *Biochemical and Biophysical Research Communications*, vol. 417, no. 4, pp. 1292–1297, 2012.

[38] V. S. Thakur, K. Gupta, and S. Gupta, “Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases,” *International Journal of Oncology*, vol. 33, no. 2, pp. 377–384, 2012.